pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag International N.V clinical programs — 54 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
Janssen-Cilag International N.V projects
54 ClinicalTrials.gov programs sponsored by Janssen-Cilag International N.V.
Janssen-Cilag International N.V has 54 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A study to evaluate how the body absorbs for Healthy Volunteers
Janssen-Cilag International N.V.
Healthy Volunteers
1 trial -
Characterization of Immune Response in Participants from a Posdinemab Study
Janssen-Cilag International N.V.
Early Alzheimer's disease
1 trial -
PLATFORMPACAN1001
Janssen-Cilag International N.V.
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
1 trial -
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
Janssen-Cilag International N.V.
Non-Hodgkin Lymphoid Malignancies (NHLs)
1 trial -
Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer
Janssen-Cilag International N.V.
Metastatic colorectal cancer and Gastric cancer
1 trial -
TMC207TBC1006
Janssen-Cilag International N.V.
Tuberculosis
1 trial
Frequently asked questions
How many clinical projects does Janssen-Cilag International N.V have?
54 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.